Blow to Ranbaxy Drug Research Plans (India)
This article was originally published in PharmAsia News
Medicines for Malaria Venture (MMV), a World Health Organization agency, has announced that it is pulling out of its partnership with Ranbaxy Laboratories Ltd. to develop a anti-malarial drug. Since 2003, Ranbaxy, India's second-largest drug manufacturer, has been working with MMV to create a man-made version of Arterolane, a Chinese herbal remedy for malaria. Ranbaxy recently completed Phase II clinical trials on Arterolane. MMV had also performed several studies on the drug. MMV representatives say the decision to end their involvement in the project was the result of Arterolane's less-than-stellar performance in those trials. Despite the setback, Ranbaxy has said it will continue to develop the new drug and hope to have it ready to market by 2011. (Click here for more
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.